Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Electrochemical biosensor for early Alzheimer's detection and patient risk stratification using plasma exosomes

  • Rossi, Rosanna|||0000-0002-3656-2908
  • Cano, Amanda|||0000-0001-9567-4283
  • Pallarès-Rusiñol, Arnau|||0000-0001-9990-148X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
Alzheimer's Disease (AD) is the leading cause of dementia, accounting for 60-70 % of cases worldwide. Early diagnosis remains challenging due to the limitations of current diagnostic tools, which are costly, invasive, and suffer from low patient compliance. Blood-based biomarkers, particularly plasma brain-derived exosomes (BDEs), have emerged as a promising alternative since they carry AD-related molecules and can be isolated non-invasively. In this study, an immunoassay was developed to isolate BDEs using magnetic particles functionalized with an anti-neuroligin-3 (NLGN3) antibody, while the AD-related marker β-secretase (BACE-1) was detected on the captured exosomes. This is the first report combining NLGN3 for for the isolation of BDEs with BACE-1 as a detection target, establishing a novel biomarker panel for AD diagnostics. The assay was evaluated across three readout platforms-optical, chemiluminescent, and electrochemical-with detection limits in the range of 104-105 exosomes μL-1. Among them, the portable electrochemical platform achieved the improved LOD (1.51 × 104 exosomes μL-1, R2 = 0.9829). Plasma samples from patients with AD, mild cognitive impairment (MCI), and healthy controls were analyzed, revealing differences in exosomal BACE-1 levels (p < 0.1, t-test). These findings demonstrate, for the first time, an in vitro diagnostic approach based on a portable electrochemical biosensor for early AD detection in plasma through a novel exosomal biomarker panel. Compared to conventional diagnostics, this biosensor offers a non-invasive and cost-effective solution for AD screening, with the potential to support earlier intervention and patient risk stratification.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exosome Biomarker Profiling Using a Paper-Based Vertical Flow Assay

  • Pallarès-Rusiñol, Arnau|||0000-0001-9990-148X
  • Marfà, Jennifer|||0000-0001-5321-3841
  • Rossi, Rosanna|||0000-0002-3656-2908
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
Exosomes are nanoscale extracellular vesicles that carry valuable biomolecular information. However, their characterization still depends on complex and costly techniques such as flow cytometry. In this study, a paper-based Vertical Flow Assay (VFA) specifically designed for the detection and profiling of exosomes derived from metastatic breast cancer cell lines is presented. The assay operates in an ELISA-like format, targeting exosomal surface proteins (CD9, CD63, CD81, and EGFR1) with specific antibodies and a secondary antibody conjugated to alkaline phosphatase. Upon reaction with the NBT/BCIP substrate, an insoluble indigo precipitate forms on the nitrocellulose membrane, generating a visual signal that can be further quantified by smartphone imaging. The VFA was optimized for membrane type, pore size, and blocking agents, reaching a detection limit of ~6 × 107 exosomes µL-1 in less than 20 min. Comparative studies with bead-based flow cytometry confirmed consistent biomarker expression profiles, demonstrating the reliability of the method. By enabling exosome biomarker profiling in a simplified and low-cost format, this approach provides a promising alternative to flow cytometry and other applications required for exosome characterization.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Competitive magneto enzyme-linked miRNA assay for quantification of microRNAs in exosomes

  • Bernuz, Mireia|||0000-0002-2052-6902
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
MicroRNAs (miRNAs) are non-coding, short RNA sequences involved in gene regulation. Although intracellular molecules, miRNAs are also found in biological fluids, where they serve as promising diagnostic and prognostic biomarkers. In liquid biopsies, miRNAs are protected from RNase activity through association with proteins or as part of the exosomal cargo. Current methods for miRNA detection are technically demanding and resource intensive. Here, we present a competitive magneto enzyme-linked miRNA (ELmiRNA) assay for the direct quantification of miRNAs in exosomes. The assay is based on a DNA scaffold containing two miRNA templates, each hybridized to a complementary double-tagged probe and anchored via a poly(A) tail to oligo(dT)-magnetic particles. Upon incubation with miRNA-containing samples, displacement of the tagged probes occurs, enabling indirect quantification through enzymatic labeling. As proof of concept, miRNA-21 and miRNA-27a, both upregulated in breast cancer, were quantified in MCF-7 and MDA-MB-231 cells and their derived exosomes. The assay achieved limits of detection of 1.5 nM (9.6 pg μL) and 2.7 nM (16.2 pg μL) for miRNA-21 and miRNA-27a, respectively, and yielded 10-30 copies per exosome, in agreement with RT-qPCR validation. The ELmiRNA assay combines sensitivity and selectivity with high-throughput analysis using a routine laboratory filter-based microplate reader. This approach represents a simplified, amplification-free alternative to RT-qPCR for miRNA quantification in exosomes, suitable for routine implementation in standard clinical and research laboratories.
Dipòsit Digital de Documents de la UAB
Publicación Artículo preliminar (WorkingPaper)

A peripheral proteomic signature of Alzheimer's disease is identified in the plasma extracellular vesicles of mild cognitive impairment patients from a memory clinic, the BIOPEXAL study

  • Capdevila-Bayo, Maria
  • Rossi, Rosanna|||0000-0002-3656-2908
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Guzman, Laura
  • Carrasco Exposito, Marina|||0000-0001-8301-8000
  • Muñoz-Morales, Álvaro
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • García-González, Pablo|||0000-0003-0125-5403
  • Bayón-Buján, Paula
  • Miguel-Romero, Andrea
  • Calm, Berta
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tatinya, Natalia
  • Martínez, Marta
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Sanz Cartagena, Mª Pilar
  • Fernández, Mª Victoria
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Montalban, Xavier|||0000-0002-0098-9918
  • Camins, Antoni|||0000-0002-1229-5956
  • Ramírez-Reveco, Alfredo|||0000-0003-4782-4261
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Cano, Amanda|||0000-0001-9567-4283
Aims: Alzheimer's disease (AD) is commonly diagnosed when neuronal damage is already established and irreversible. Achieving an accurate differential diagnosis in the preclinical and mild cognitive impairment (MCI) stage is one of the greatest challenges nowadays. Nanotechnological analysis of plasma extracellular vesicles (pEVs) are gaining attention as a promising tool for the early detection of AD pathology. This study aims to evaluate the proteomic profile of pEVs from patients with MCI and AD dementia to explore their potential as AD screening tools. Methods: pEVs were isolated by ultracentrifugation from 144 patients with MCI A-T-, MCI A+T+, and AD dementia. Nanoparticle tracking analysis and cryo-TEM were used to characterize the pEVs. CSF, serum and pEVs proteomics were carried out by using the multiplex PEA technology of Olink® proteomics, Inflammation and Neurology Explore 384 panels (768 proteins). Results: Characterization results showed that isolated plasma fraction corresponded in shape, size and concentration to EVs. Many pEVs neurology proteins involved in AD pathology significantly correlated (r > ± 0.30, p < 0.05) with their CSF homonyms, but not with their serum's. pEVs' proteome correlated with common AD signatures (CSF Aβ42 and pTau181, plasma pTau181, MMSE, NBACE, and Qalb) showing similar patterns to those observed with CSF biomarkers. Several pEVs neurology proteins didn't exhibit differences between the MCI A+T+ and AD dementia groups, whilst they did with MCI A-T-. Proteins in pEVs showed strong correlations with several measures of brain atrophy in MRI. Several neurology pEV proteins predicted conversion from MCI to AD dementia. Moreover, some of these showed a significant diagnostic accuracy of AD pathology. Conclusion: Preliminary results suggest that EVs biomarker signature could reflect AD pathology in the prodromal stages of AD continuum. However, further experiments are still needed for a better understanding of EVs' role in AD development and pathology dissemination.